查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年止血剂市场预测：按产品类型、配方、适应症、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383411

到 2030 年止血剂市场预测：按产品类型、配方、适应症、应用、最终用户和地区进行的全球分析

Hemostats Market Forecasts to 2030 - Global Analysis By Product Type, Formulation, Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球止血剂市场规模将达到 27 亿美元，预计 2030 年将达到 48 亿美元，预测期内年复合成长率为 8.7%。

止血钳是一种透过夹持、密封或压迫血管、组织来控制出血的医疗器械。止血材料是外科手术中的宝贵工具，可确保手术场无血并协助准确、安全的介入。止血材料可防止过度出血，并最大限度地降低手术期间出血和併发症的风险。

根据美国心臟协会2020年7月发布的报告，美国年度冠状动脉绕道手术绕道手术（CABG）手术量约24万例。

手术数量增加

随着世界人口的增长和高龄化，从心血管和整形外科手术到创伤和癌症相关手术等各个医学领域对外科手术的需求持续增加。止血材料在这些手术期间控制出血方面发挥重要作用，有助于病人安全和手术成功。随着手术技术的进步和手术选择的扩大，对有效且高效的止血装置的需求变得显而易见。手术数量的增加凸显了止血装置在维持止血、减少失血和改善患者预后方面发挥的重要作用。

紧急情况下有限使用

止血材料对于手术过程中控制出血至关重要，但其应用在快速、高压力的紧急情况下（例如创伤治疗和战地医学）可能受到限制。在这种情况下，需要一种能够可靠且几乎立即止血的止血材料。需要复杂的使用程序或特殊条件的止血材料可能无法满足此类危急情况的需求。克服这些限制需要开发专门的止血材料，旨在在紧急情况下快速有效地使用，以挽救生命并防止严重出血。

降低医疗成本

透过最大限度地减少出血、减少输血需求和缩短手术时间，止血剂有助于降低医疗成本。这些经济高效的解决方案可改善资源分配、减少术后併发症并改善患者治疗效果。在医疗保健成本控制至关重要的环境中，兼具临床疗效和经济效益的止血剂产品能够很好地应对这些机会并获得市场吸引力。

严格法规的变化

不断变化的法规和日益严格的安全标准可能会影响止血剂的核准、配製和商业化。跟上不断变化的法规可能既耗时又昂贵，导致市场进入延迟并增加开发成本。面临的挑战是满足新的要求，同时保持产品的安全性和有效性。法规的不确定性和对全面文件的需求增加了开发过程的复杂性。这些因素可能会阻碍创新，限制新型止血解决方案的推出，并降低市场响应医疗保健专业人员和患者不断变化的需求的能力。

COVID-19 的影响：

COVID-19大流行对止血材料市场产生了各种影响。危重手术和创伤护理领域对止血材料的需求仍然很高，但疫情扰乱了供应链并影响了某些产品的可得性。此外，选择性手术被推迟或取消，暂时减少了整体市场需求。由于医疗机构专注于 COVID-19 治疗，因此对止血等其他医疗需求的关注度出现了波动。然而，随着维持稳健的医疗基础设施的重要性和对紧急止血剂的需求变得更加清晰，以及随着医疗保健系统适应未来的挑战，大流行后市场将会成长，并可能增强弹性。

预计在预测期内基于凝血酶的止血剂市场将是最大的

基于凝血酶的止血剂市场预计将出现良好的成长。这些产品含有凝血酶，一种启动血液凝固过程的酵素。当应用于出血部位时，基于凝血酶的止血剂会透过将可溶性纤维蛋白原转化为不溶性纤维蛋白链来促进凝块形成，最终形成稳定的血块。其多功能性使其适用于各种外科手术，从心血管和整形外科手术到肝切除和创伤治疗。以凝血酶为基础的止血剂可快速、精确地控制出血，降低出血及其相关併发症的风险。基于凝血酶的止血材料具有实绩的止血效果，在医疗领域备受信赖，从而提高了其在整个止血材料市场中的地位。

预计医院领域在预测期内的年复合成长率最高。

预计医院产业在预测期内将以最快的年复合成长率成长。从大型学术医疗中心到社区医院，这些医疗机构在各种外科手术过程中都依赖止血材料来控制出血。止血材料是确保手术场无血的重要工具，以便医疗专业人员能够准确、安全地进行手术。无论是择期手术或急诊手术，对手术介入的持续需求强调了医院止血材料的重要性。此外，包括微创技术在内的先进手术技术的采用，进一步增加了对有效止血材料的需求，医院继续关注病患安全、成功的手术结果和业务开拓。止血材料市场。

比最大的地区

预计北美市场在预测期内将继续占据大部分市场占有率。该地区拥有完善的医疗基础设施、先进的医疗技术和大量的外科手术。从心血管手术和整形外科手术到创伤护理，各种医学专业对止血材料和设备的需求仍然很高。严格的法规标准和对病人安全的关注正在推动创新止血解决方案的开发和采用。此外，慢性病的流行和高龄化进一步增加了对有效止血材料的需求。

复合年复合成长率最高的地区：

亚太地区在市场中发挥重要作用，预计在预测期内年复合成长率最高。医疗投资的增加、医疗基础设施的扩建以及患者人数的增加为止血材料和设备的采用创造了有利的环境。随着手术数量的增加，对有效止血解决方案的需求不断增加，特别是中国和印度等国家。此外，该地区对负担得起的医疗保健解决方案的关注、医疗旅游的趋势和获得医疗保健的机会也正在推动市场成长。

免费客製化服务：

订阅此报告的客户将收到以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球止血材料市场：依产品类型

  • 基于凝血酶的止血剂
  • 氧化再生纤维素基止血材料
  • 复合止血材料
  • 纤维蛋白密封剂
  • 明胶止血材料
  • 胶原蛋白止血材料
  • 其他产品类型

第6章全球止血剂市场：依配方分类

  • 基质和凝胶止血材料
  • 片材和垫片止血材料
  • 海绵止血材料
  • 粉末止血剂
  • 其他处方

第7章全球止血剂市场：依适应症分类

  • 关闭
  • 外科手术

第8章全球止血材料市场：依应用分类

  • 整形外科
  • 一般外科
  • 神经外科
  • 心血管外科
  • 重组手术
  • 妇科手术
  • 整形外科
  • 其他用途

第9章全球止血材料市场：依最终用户分类

  • 门诊中心
  • 医院
  • 诊所
  • 社区健康保健
  • 其他最终用户

第10章全球止血材料市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Ethicon, Inc
  • Becton Dickinson and Company
  • Marine Polymer Technologies, Inc
  • Pfizer, Inc
  • Johnson & Johnson Services, Inc
  • Integra Lifesciences Corporation
  • Hemostatis LLC
  • Z-Medica LLC
  • Medtronic plc
  • Gelita Medical GmbH
  • Stryker Corporation
  • Baxter International, Inc
  • Teleflex Incorporated
  • Anika Therapeutics, Inc
  • B. Braun Melsungen AG
  • CR Bard, Inc.
Product Code: SMRC24260

According to Stratistics MRC, the Global Hemostats Market is accounted for $2.7 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Hemostats are medical instruments used to control bleeding by either clamping, sealing, or compressing blood vessels, tissues, or vessels. They are valuable tools in surgical procedures to ensure a bloodless surgical field, aiding in accurate and safe interventions. Hemostats help prevent excessive blood loss, minimizing the risk of hemorrhage and complications during surgery.

According to a report published by American Heart Association in July 2020, the annual number of Coronary Artery Bypass Graft (CABG) surgeries is around 240,000 in the U.S. All these trends are expected to increase demand for hemostatic agents.

Market Dynamics:

Driver:

Rising number of surgical procedures

As the global population grows and ages, the demand for surgical interventions continues to increase, spanning various medical fields, from cardiovascular and orthopedic surgeries to trauma and cancer-related procedures. Hemostatic agents play a crucial role in controlling bleeding during these surgeries, contributing to patient safety and surgical success. With advancements in surgical techniques and a broader array of surgical options available, the need for effective and efficient hemostatic tools becomes more pronounced. This growing surgical volume underscores the pivotal role hemostats play in maintaining hemostasis, reducing blood loss, and improving patient outcomes.

Restraint:

Limited use in emergency settings

While hemostatic agents are crucial in controlling bleeding during surgical procedures, their applicability in rapid and high-stress emergency situations, such as trauma care and battlefield medicine, can be restricted. In these scenarios, there is a need for hemostatic products that offer near-instantaneous and reliable hemostasis. Hemostats that require complex application procedures or specific conditions may not meet the demands of these critical situations. Overcoming this restraint requires the development of specialized hemostatic solutions designed for quick and effective use in emergencies, where every moment counts in saving lives and preventing severe hemorrhage.

Opportunity:

Healthcare cost reduction

By minimizing blood loss, reducing the need for blood transfusions, and shortening surgical times, hemostatic agents contribute to lower healthcare expenses. These cost-effective solutions improve resource allocation, reduce postoperative complications, and enhance patient outcomes, which can ultimately translate to reduced hospitalization costs and healthcare expenditures. In an environment where healthcare cost containment is a paramount concern, hemostatic products that offer both clinical effectiveness and economic advantages are well-positioned to address this opportunity and gain traction in the market.

Threat:

Stringent regulatory changes

Evolving regulations and heightened safety standards can impact the approval, formulation, and commercialization of hemostatic products. Compliance with these ever-changing regulations can be time-consuming and costly, leading to potential delays in market entry and increased development expenses. The challenge lies in adapting to new requirements while maintaining product safety and efficacy. Regulatory uncertainties and the need for comprehensive documentation add complexity to the development process. These factors can hinder innovation, limit the introduction of novel hemostatic solutions, and potentially reduce the market's ability to address the evolving needs of healthcare providers and patients.

COVID-19 Impact:

The COVID-19 pandemic had a mixed impact on the hemostats market. While the demand for hemostatic agents remained high during critical surgeries and trauma care, the pandemic disrupted supply chains, affecting the availability of some products. Additionally, elective surgical procedures were postponed or canceled, temporarily reducing the overall market demand. As healthcare facilities focused on COVID-19 treatment, the attention to other medical needs, including hemostasis, fluctuated. However, the importance of maintaining a robust healthcare infrastructure and the need for hemostats in emergencies became more evident, potentially driving greater resilience in the market post-pandemic as healthcare systems adapt to meet future challenges.

The thrombin-based hemostats segment is expected to be the largest during the forecast period

The thrombin-based hemostats segment is expected to have a lucrative growth. These products contain thrombin, an enzyme responsible for initiating the blood clotting process. When applied to a bleeding site, thrombin-based hemostats accelerate clot formation by converting soluble fibrinogen into insoluble strands of fibrin, ultimately leading to the formation of a stable blood clot. Their versatility makes them suitable for a wide range of surgical procedures, from cardiovascular and orthopedic surgeries to liver resections and trauma care. Thrombin-based hemostats offer rapid and precise control over bleeding, reducing the risk of hemorrhage and associated complications. Their proven track record in achieving hemostasis continues to make them a trusted choice in the medical field, contributing to their prominence within the broader hemostats market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These medical facilities, ranging from large academic medical centers to community hospitals, rely on hemostats to control bleeding during a diverse array of surgical procedures. Hemostatic agents are essential tools that ensure a bloodless surgical field, enabling healthcare providers to perform surgeries with precision and safety. The constant demand for surgical interventions, whether elective or emergency, underscores the importance of hemostats in hospitals. Moreover, the adoption of advanced surgical techniques, including minimally invasive procedures, further amplifies the need for effective hemostatic products, hospitals' ongoing focus on patient safety, successful surgical outcomes, and operational efficiency continues to drive the growth and development of the hemostats market.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region boasts a well-established healthcare infrastructure, advanced medical technology, and a high volume of surgical procedures. The demand for hemostatic agents and devices remains consistently strong across various medical specialties, from cardiac and orthopedic surgeries to trauma care. Stringent regulatory standards and a focus on patient safety drive the development and adoption of innovative hemostatic solutions. Additionally, the prevalence of chronic diseases and an aging population further amplifies the need for effective hemostats.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the market and is projected to have the highest CAGR over the forecast period. The increasing healthcare investments, expanding healthcare infrastructure, and a growing patient population create a favorable environment for the adoption of hemostatic agents and devices. With rising surgical volumes, particularly in countries like China and India, the demand for effective hemostatic solutions is on the ascent. Additionally, the region's focus on affordable healthcare solutions, growing trend of medical tourism and access to medical care drives the market's growth.

Key players in the market

Some of the key players in Hemostats market include: Ethicon, Inc, Becton Dickinson and Company, Marine Polymer Technologies, Inc, Pfizer, Inc, Johnson & Johnson Services, Inc, Integra Lifesciences Corporation, Hemostatis LLC, Z-Medica LLC, Medtronic plc, Gelita Medical GmbH, Stryker Corporation, Baxter International, Inc, Teleflex Incorporated, Anika Therapeutics, Inc, B. Braun Melsungen AG and CR Bard, Inc.

Key Developments:

In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.

In July 2023, Baxter International (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients.

Product Types Covered:

  • Thrombin-based Hemostats
  • Oxidized Regenerated Cellulose-based Hemostats
  • Combination Hemostats
  • Fibrin Sealants
  • Gelatin-based Hemostats
  • Collagen-based Hemostats
  • Other Product Types

Formulations Covered:

  • Matrix & Gel Hemostats
  • Sheet & Pad Hemostats
  • Sponge Hemostats
  • Powder Hemostats
  • Other Formulations

Indications Covered:

  • Closure
  • Surgery

Applications Covered:

  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Reconstructive Surgery
  • Gynecological Surgery
  • Plastic Surgery
  • Other Applications

End Users Covered:

  • Ambulatory Centers
  • Hospitals
  • Clinics
  • Community Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hemostats Market, By Product Type

  • 5.1 Introduction
  • 5.2 Thrombin-based Hemostats
  • 5.3 Oxidized Regenerated Cellulose-based Hemostats
  • 5.4 Combination Hemostats
  • 5.5 Fibrin Sealants
  • 5.6 Gelatin-based Hemostats
  • 5.7 Collagen-based Hemostats
  • 5.8 Other Product Types

6 Global Hemostats Market, By Formulation

  • 6.1 Introduction
  • 6.2 Matrix & Gel Hemostats
  • 6.3 Sheet & Pad Hemostats
  • 6.4 Sponge Hemostats
  • 6.5 Powder Hemostats
  • 6.6 Other Formulations

7 Global Hemostats Market, By Indication

  • 7.1 Introduction
  • 7.2 Closure
  • 7.3 Surgery

8 Global Hemostats Market, By Application

  • 8.1 Introduction
  • 8.2 Orthopedic Surgery
  • 8.3 General Surgery
  • 8.4 Neurological Surgery
  • 8.5 Cardiovascular Surgery
  • 8.6 Reconstructive Surgery
  • 8.7 Gynecological Surgery
  • 8.8 Plastic Surgery
  • 8.9 Other Applications

9 Global Hemostats Market, By End User

  • 9.1 Introduction
  • 9.2 Ambulatory Centers
  • 9.3 Hospitals
  • 9.4 Clinics
  • 9.5 Community Healthcare
  • 9.6 Other End Users

10 Global Hemostats Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Ethicon, Inc
  • 12.2 Becton Dickinson and Company
  • 12.3 Marine Polymer Technologies, Inc
  • 12.4 Pfizer, Inc
  • 12.5 Johnson & Johnson Services, Inc
  • 12.6 Integra Lifesciences Corporation
  • 12.7 Hemostatis LLC
  • 12.8 Z-Medica LLC
  • 12.9 Medtronic plc
  • 12.10 Gelita Medical GmbH
  • 12.11 Stryker Corporation
  • 12.12 Baxter International, Inc
  • 12.13 Teleflex Incorporated
  • 12.14 Anika Therapeutics, Inc
  • 12.15 B. Braun Melsungen AG
  • 12.16 CR Bard, Inc.

List of Tables

  • Table 1 Global Hemostats Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hemostats Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Hemostats Market Outlook, By Thrombin-based Hemostats (2021-2030) ($MN)
  • Table 4 Global Hemostats Market Outlook, By Oxidized Regenerated Cellulose-based Hemostats (2021-2030) ($MN)
  • Table 5 Global Hemostats Market Outlook, By Combination Hemostats (2021-2030) ($MN)
  • Table 6 Global Hemostats Market Outlook, By Fibrin Sealants (2021-2030) ($MN)
  • Table 7 Global Hemostats Market Outlook, By Gelatin-based Hemostats (2021-2030) ($MN)
  • Table 8 Global Hemostats Market Outlook, By Collagen-based Hemostats (2021-2030) ($MN)
  • Table 9 Global Hemostats Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 10 Global Hemostats Market Outlook, By Formulation (2021-2030) ($MN)
  • Table 11 Global Hemostats Market Outlook, By Matrix & Gel Hemostats (2021-2030) ($MN)
  • Table 12 Global Hemostats Market Outlook, By Sheet & Pad Hemostats (2021-2030) ($MN)
  • Table 13 Global Hemostats Market Outlook, By Sponge Hemostats (2021-2030) ($MN)
  • Table 14 Global Hemostats Market Outlook, By Powder Hemostats (2021-2030) ($MN)
  • Table 15 Global Hemostats Market Outlook, By Other Formulations (2021-2030) ($MN)
  • Table 16 Global Hemostats Market Outlook, By Indication (2021-2030) ($MN)
  • Table 17 Global Hemostats Market Outlook, By Closure (2021-2030) ($MN)
  • Table 18 Global Hemostats Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 19 Global Hemostats Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Hemostats Market Outlook, By Orthopedic Surgery (2021-2030) ($MN)
  • Table 21 Global Hemostats Market Outlook, By General Surgery (2021-2030) ($MN)
  • Table 22 Global Hemostats Market Outlook, By Neurological Surgery (2021-2030) ($MN)
  • Table 23 Global Hemostats Market Outlook, By Cardiovascular Surgery (2021-2030) ($MN)
  • Table 24 Global Hemostats Market Outlook, By Reconstructive Surgery (2021-2030) ($MN)
  • Table 25 Global Hemostats Market Outlook, By Gynecological Surgery (2021-2030) ($MN)
  • Table 26 Global Hemostats Market Outlook, By Plastic Surgery (2021-2030) ($MN)
  • Table 27 Global Hemostats Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global Hemostats Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Hemostats Market Outlook, By Ambulatory Centers (2021-2030) ($MN)
  • Table 30 Global Hemostats Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 Global Hemostats Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 32 Global Hemostats Market Outlook, By Community Healthcare (2021-2030) ($MN)
  • Table 33 Global Hemostats Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.